On April 12, 2026 GSK plc (LSE/NYSE: GSK) reported positive findings from its global phase I BEHOLD-1 clinical trial for mocertatug rezetecan (or Mo-Rez for short), a novel antibody-drug conjugate (ADC) targeting the B7-H4 antigen. At the highest doses evaluated, Mo-Rez monotherapy achieved confirmed objective response rates (cORR) of 62% (5.8 mg/kg n=21/34; 95% CI: 44, 78) in platinum-resistant ovarian cancer (PROC) and 67% (4.8 mg/kg n=8/12; 95% CI: 35, 90) in recurrent or advanced endometrial cancer (EC).1 These data will be presented for the first time in a late-breaking oral session at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer in San Juan, Puerto Rico.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Currently, there are limited treatment options with modest response rates for patients with PROC and advanced EC. B7-H4 is an immune checkpoint that is widely expressed in ovarian and endometrial cancers and is low in normal tissues, providing potential for a differentiated precision-therapy. The response to Mo-Rez observed across a range of B7-H4 expression levels reinforces its broad potential in gynaecologic cancers and further validates the relevance of targeting B7-H4.

Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: "Treatment of gynaecological cancers remains a major challenge, with a pressing need for new therapies that offer improved response rates. With Mo-Rez, we now have compelling evidence of a promising clinical profile, with response rates that support accelerating development into five pivotal global phase III trials later this year across ovarian and endometrial cancers, including earlier line settings."

Ana Oaknin, Study Investigator for BEHOLD-1, Medical Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain said: "In the early phase BEHOLD-1 study, we saw meaningful antitumour activity for this patient dataset, with response rates higher than typically seen in ADCs in development, and a manageable safety profile. For patients with platinum-resistant ovarian cancer and recurrent endometrial cancer, these findings are particularly encouraging."

At the highest doses evaluated in BEHOLD-1, few patients needed to stop treatment because of a treatment-related adverse events (TRAE) (0% in PROC and 4% in EC). The most common TRAE was nausea (82% in PROC; 75% in EC). Grade ≥3 TRAEs occurred in 64% and 54% patients in PROC and EC, respectively, and were predominantly haematologic, as expected for treatments in this class. Overall rates of interstitial lung disease or pneumonitis were low (3%; 5 out of 178 patients) and all cases were mild to moderate (grade 1-2). The interim analysis showed the median duration of response had not yet been reached. Based on the findings from this study, the recommended dose for the first of the phase III trials, BEHOLD-Ovarian01 and BEHOLD-Endometrial01, is 5.8 mg/kg.

About the BEHOLD clinical trial programme
The BEHOLD clinical programme is GSK’s global development plan that includes the BEHOLD-1 (NCT06431594) monotherapy study and the ongoing BEHOLD-2 (NCT06796907) combination study. Mo-Rez will advance to five pivotal global phase III trials in 2026, starting with PROC (BEHOLD-Ovarian01 / NCT07286266) and 2L EC (BEHOLD-Endometrial01 / NCT07286331). Additional phase III studies will evaluate Mo‑Rez in platinum‑sensitive ovarian cancer (BEHOLD-Ovarian02) and in first‑line maintenance settings for ovarian cancer without homologous recombination deficiency (BEHOLD-Ovarian03) and mismatch‑repair–proficient endometrial cancer (BEHOLD-Endometrial02).

About BEHOLD-1
The BEHOLD-1 clinical trial is a two-part, open-label, phase I study evaluating the safety, tolerability and efficacy of Mo-Rez injection in patients with PROC or advanced/recurrent EC. Phase Ia assessed up to four Mo-Rez dose levels in patients with advanced solid tumours, with intravenous administration every three weeks until progression or toxicity. In the phase Ib dose expansion, patients with PROC or EC (1–3 prior lines of therapy) were randomised to three or two Mo-Rez dose levels, respectively.

At data cut-off, a total of 224 patients were enrolled in BEHOLD-1; n=44 in phase 1a (n=21 PROC, n=23 mix of other solid tumours) and n=180 in phase Ib (n=131 PROC, n=49 EC). Primary endpoints included: incidence of dose-limiting toxicity in phase Ia and confirmed ORR (cORR) by investigator per RECIST 1.1 in phase Ib. At the highest dose evaluated in phase Ib, the most common adverse events in PROC were nausea (86%), neutropenia/neutrophil count decreased (73%), anaemia (52%), fatigue (52%) and alopecia (52%). In EC, the most common adverse events were nausea (79%), neutropenia/neutrophil count decreased (58%), anaemia (54%), vomiting (46%) and fatigue (42%). Treatment related adverse events led to dose interruptions in 39% of patients with PROC and 21% of those with EC, and to dose reductions in 39% in PROC and 17% in EC, at the highest dose. The trial is ongoing and currently in the dose expansion phase.

About mocertatug rezetecan
Mo-Rez is a novel investigational B7-H4-targeted antibody-drug conjugate designed to optimise efficacy and tolerability. It is composed of a fully human anti-B7-H4 monoclonal antibody covalently linked to a topoisomerase inhibitor payload and has a drug-to-antibody ratio (DAR) of 6. GSK acquired exclusive worldwide rights (excluding China’s mainland, Hong Kong, Macau, and Taiwan) from Hansoh Pharma to progress clinical development and commercialisation of Mo-Rez globally.

About ovarian cancer and endometrial cancer
Endometrial cancer affects 1.6 million people globally, with 417,000 new cases each year and 15% to 20% of patients presenting in later stages of the disease.2,3 Ovarian cancer affects 843,000 people with 240,000 new cases annually.4 70% of these patients present with advanced disease.5 Recurrence is common in advanced cases of disease, up to 67% in endometrial cancer and 70% in ovarian cancer, and survival usually declines after recurrence.

(Press release, GlaxoSmithKline, APR 12, 2026, View Source [SID1234664307])

On April 11, 2026 BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") reported positive results from the primary analysis of a Phase 2 cohort evaluating trastuzumab pamirtecan (BNT323/DB-1303) in patients with HER2-expressing, advanced endometrial cancer whose disease progressed on or after first-line chemotherapy with or without prior checkpoint inhibitor treatment. This cohort is part of a global Phase 1/2a clinical trial (NCT05150691) investigating the HER2-targeted antibody-drug conjugate ("ADC") candidate trastuzumab pamirtecan in multiple solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The data demonstrated clinically meaningful efficacy and a manageable safety profile for trastuzumab pamirtecan monotherapy across all HER2 immunohistochemistry ("IHC") expression levels (IHC1+, IHC2+, IHC3+)ii. Outcomes were consistent among patients regardless of prior checkpoint inhibitor treatment. The data will be presented today in an oral session at the 2026 Society of Gynecologic Oncology ("SGO") Annual Meeting on Women’s Cancers in San Juan, Puerto Rico.

"Endometrial cancer is one of the few cancers with an increasing mortality rate,1 and there is an urgent need for new treatment options, especially for patients with recurrent disease with lower HER2 expression levels where current standard-of-care chemotherapy offers only a 15 % response rate2," said Bhavana Pothuri, M.D., Medical Director of the Clinical Trials Office (CTO) and Director of Gynecologic Oncology Research at the NYU Langone Perlmutter Cancer Center. "We are encouraged by these results for trastuzumab pamirtecan, which showed clinically meaningful responses across all HER2 levels. Importantly, these results were seen in a broad patient population that reflects real-world clinical practice, including patients who have received prior immune checkpoint inhibitor treatment and those with visceral metastases."

The analysis of the Phase 2 cohort included 145 patients with advanced or metastatic HER2-expressing endometrial cancer whose disease had progressed following first- or later lines of therapy. This cohort met its primary efficacy endpoint of objective response rate ("ORR") evaluated in 73 patients previously treated with checkpoint inhibitor therapy and confirmed HER2 status by central testing, showing a confirmed ORR of 49.3% (95% CI: 37.4, 61.3). In all centrally tested patients (n=96) the confirmed ORR was 47.9% (95% CI: 37.6, 58.4) with a median progression-free survival ("mPFS") of 8.1 months (95% CI: 5.5, 11.8).

Among the 143 efficacy-evaluable patients by locali HER2 status testing, the confirmed ORR was 44.1% (95% CI: 35.8, 52.6). Trastuzumab pamirtecan consistently demonstrated encouraging antitumor activity across all HER2 expression levels, with comparable results whether HER2 testing was conducted locally or centrally. Among patients with local HER2 testing, the confirmed ORR was 33.9% (IHC1+) and 40.4% (IHC2+) in patients with lower levels of HER2 expression, and 73.1% (IHC3+) in patients with higher HER2 expression levels. The median duration of response ("mDoR") was 10.3 months. mPFS for all evaluable patients (n=145), whether they had received prior checkpoint inhibitor treatment or not, was 8.0 months (95% CI: 5.6, 8.3).

The safety profile was manageable and as expected for HER2-targeted ADCs. The most common treatment-related adverse events (TRAEs) were low-grade nausea, anemia, platelet count decrease, and low-grade fatigue. Grade ≥3 treatment-related adverse events (TRAEs) were reported in 68 of 145 (46.9%) patients. Adjudicated cases of interstitial lung disease ("ILD") or pneumonitis of grade ≥3 occurred in 4.8% of patients and were consistent with the known safety profile of HER2-targeted ADC therapies. The majority of events grade 3 or higher were efficiently manageable with appropriate medical interventions.

"These positive results in patients with endometrial cancer including those with lower HER2 expression levels support the potential of trastuzumab pamirtecan," said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. "HER2 remains an important therapeutic target, particularly in gynecologic cancers and breast cancer. We are continuing to advance trastuzumab pamirtecan, both as a monotherapy and in novel-novel treatment combination approaches, with the aim to address the significant unmet medical needs in the treatment of patients with HER2-driven tumors."

Trastuzumab pamirtecan received Fast Track and Breakthrough Therapy designations from the U.S. Food and Drug Administration ("FDA") for the treatment of endometrial cancer in 2023. A global confirmatory Phase 3 clinical trial Fern-EC-01 (NCT06340568) evaluating trastuzumab pamirtecan monotherapy compared to chemotherapy in previously treated patients with HER2-expressing, recurrent endometrial cancer is ongoing. BioNTech and DualityBio plan to file a biologics license application ("BLA") in 2026, subject to regulatory feedback from the FDA.

About trastuzumab pamirtecan
Trastuzumab pamirtecan (BNT323/DB-1303) is a third-generation topoisomerase-1 inhibitor-based ADC targeting HER2 and is being developed by BioNTech and Duality Biologics. Trastuzumab pamirtecan was built from DualityBio’s proprietary Duality Immune Toxin Antibody Conjugates ("DITAC") platform. HER2 is a surface-expressed protein on solid tumors and has been linked to the aggressive growth and spread of cancer cells. Preclinical data and preliminary clinical data for trastuzumab pamirtecan indicate its potential to target HER2 receptors on solid tumors irrespective of expression level with a manageable safety profile and a potentially expanded therapeutic window.

Trastuzumab pamirtecan is being evaluated in an ongoing Phase 1/2 trial (NCT05150691) in patients with advanced/metastatic solid tumors, and in two global Phase 3 clinical trials. Fern-EC-01, a randomized Phase 3 clinical trial (NCT06340568) evaluating trastuzumab pamirtecan compared with investigator’s choice of single agent chemotherapy in previously treated patients with HER2-expressing advanced recurrent endometrial cancer, is currently enrolling patients. DYNASTY-Breast02, a Phase 3 clinical trial (NCT06018337) evaluating trastuzumab pamirtecan in patients with Hormone Receptor-positive ("HR+") and Human Epidermal Growth Factor Receptor 2 ("HER2")-low, metastatic breast cancer that have progressed on hormone and/or cyclin-dependent kinase 4/6 ("CDK4/6") therapy, is fully enrolled and expected to read out this year.

About the Phase 1/2a trial
The global, multi-cohort Phase 1/2a clinical trial (NCT05150691) evaluated the safety and tolerability of trastuzumab pamirtecan in patients with advanced solid tumors that express HER2. Cohort 2b is a Phase 2 expansion cohort which enrolled 145 patients with advanced/metastatic HER2-expressing endometrial cancer whose disease had progressed after first- and later lines of therapy. The HER2 status was determined for all patients through local testing and, where possible, confirmed via central testing. The primary endpoints were objective response rate in patients with prior checkpoint inhibitor treatment with HER2 expression, confirmed by retrospective central testing, and safety. Secondary endpoints included ORR, DoR, DCR, PFS and OS.

(Press release, BioNTech, APR 11, 2026, View Source [SID1234664306])

On April 10, 2026 Vivatides Therapeutics, a global biotechnology company focused on developing extrahepatic RNA-targeting therapeutics, reported the successful closing of an oversubscribed $54 million Series A financing. The round was co-led by Qiming Venture Partners and a leading industry fund, with participation from Highlight Capital, a leading venture fund, and TF Capital. Existing investor Apricot Capital also continued to support the company with additional investment. Proceeds from the financing will be used to further advance Vivatides’ extrahepatic delivery platform, accelerate multiple pipeline programs into clinical development, and expand its global team and R&D network. As an emerging player in the RNA therapeutics field, Vivatides has completed both its seed and Series A financings within less than one year of founding, underscoring strong investor confidence in the company’s technological innovation and execution capabilities in extrahepatic RNA delivery.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

RNA therapeutics, with their broad target space, high specificity, and durable efficacy, are poised to become the third major therapeutic modality following small molecules and antibodies. However, traditional RNA therapeutics have largely been limited to liver-targeted applications due to delivery challenges. Diseases involving extrahepatic tissues remain significantly underserved and represent the next major frontier for innovation.

With advances in extrahepatic delivery technologies, RNA therapeutics are rapidly expanding beyond rare diseases into large, chronic disease areas such as hyperlipidemia, hypertension, and oncology, unlocking substantial market potential.

Founded in 2025, Vivatides has been dedicated to the innovation and translation of proprietary extrahepatic RNA delivery technologies. The company’s globally experienced leadership team includes experts from leading RNA therapeutics companies. The team has previously led or played key roles in multiple extrahepatic RNA programs, several of which have progressed into clinical development. Leveraging this deep expertise, Vivatides has built a differentiated extrahepatic delivery platform with capabilities spanning both siRNA and antisense oligonucleotides (ASO). The company has achieved key advances in ligand conjugation, delivery efficiency, tissue targeting specificity, and safety, with encouraging in vivo results already demonstrated. Combined with strong capabilities in sequence design and target discovery, the platform enables rapid parallel advancement and expansion of a diversified pipeline.

"Extrahepatic delivery is the key that will unlock RNA therapeutics from niche rare diseases to broad chronic indications," said Keming Zhou, Founder of Vivatides Therapeutics. "We are honored to have the support and recognition of leading investors. This financing will accelerate the evolution of our platform and pipeline, advancing innovative RNA therapeutics into extrahepatic disease areas. We believe that overcoming delivery barriers will enable RNA therapeutics to transform treatment paradigms across a wide range of diseases. We also look forward to engaging with more long-term, value-driven partners to bring transformative therapies to patients worldwide."

Dr. Kan Chen, Partner at Qiming Venture Partners and Co-leads Qiming’s investments in the healthcare sector, commented: " We have long been optimistic about the application potential of small nucleic acid drugs across a broader range of disease areas. Continuous advances in extrahepatic targeting technologies are steadily expanding their clinical frontiers. Vivatides Therapeutics has demonstrated solid technological expertise and efficient execution capabilities in this field, with encouraging progress achieved on its platform. We look forward to the company driving further technological breakthroughs, accelerating the clinical translation of its pipeline, and delivering safer and more effective innovative therapies to patients worldwide."

Dr. Wei Ding, Partner at Apricot Capital, commented: "As an early investor in Vivatides’ seed round, we are delighted to see the company successfully complete its Series A financing and welcome new investors. Since its founding, Dr. Zhou and his team have consistently exceeded expectations with exceptional execution in platform development and pipeline advancement. We look forward to Vivatides translating its differentiated platform into breakthrough therapies that benefit patients worldwide and leading the next wave of extrahepatic RNA therapeutics."

Following the financing, Vivatides will further accelerate preclinical optimization and IND-enabling studies, expand its R&D and management teams, and continue to strengthen its extrahepatic delivery platform. Looking ahead, the company will remain focused on addressing unmet medical needs in high-prevalence extrahepatic diseases, becoming a leader in RNA therapeutics and delivering more effective and safer treatment options to patients worldwide.

(Press release, Vivatides Therapeutics, APR 10, 2026, View Source [SID1234664305])

On April 10, 2026 IASO Biotechnology ("IASO Bio"), reported that it has signed a technology licensing agreement with the Instituto Butantan, a leading Brazilian public institution, for the local development of a CAR-T cell therapy for hematological cancer in Brazil. The technology uses the patient’s own immune cells to treat the disease.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the agreement, the cells will be developed and manufactured at the Advanced Therapies Center of São Paulo (Nutera-SP), a facility coordinated by Butantan that has specific equipment for cell therapies.

The local development of the therapy by a public institution allows for lower costs, favoring its potential future incorporation into the Unified Health System (SUS). This type of treatment can cost up to US$500,000 (R$2.6 million) per patient. Today in Brazil, this therapy is only available in the private healthcare system.

"This treatment revolutionized the fight against hematological diseases, but access to it remains a challenge. The new partnership allows the Butantan Institute, as a public institution, to expand its portfolio of advanced therapies to meet the needs of Brazilian public health, expanding access to cutting-edge technologies," says the Director of the Butantan Institute, Esper Kallás.

For the coordinator of Nutera-SP, Vanderson Rocha, Full Professor of Hematology at the University of São Paulo’s School of Medicine, the local development of CAR-T by a public institution is a milestone for Brazilian science. "In the future, the therapy could expand treatment possibilities for patients who no longer respond to conventional therapies," he says.

"This partnership with Butantan is a pivotal milestone in IASO Bio’s global strategy to bring our innovative cell therapies to patients in Latin America," said Jinhua Zhang, Founder, Chairwoman and CEO of IASO Bio. "By combining our proprietary cell therapy technology with Butantan’s exceptional development and manufacturing capabilities as a public institution, we have a unique opportunity to significantly reduce costs and make this life-saving treatment accessible to many more patients in Brazil through the public health system."

(Press release, IASO Biotherapeutics, APR 10, 2026, View Source [SID1234664304])

On April 10, 2026 Eisai Inc. reported the presentation of findings from a new survey, which evaluated the experiences and perspectives of 119 U.S.-based patients who have been diagnosed with endometrial cancer (EC) and who received at least one line of chemotherapy.† Conducted online in collaboration with the Endometrial Cancer Action Network for African-Americans (ECANA), Facing Our Risk of Cancer Empowered (FORCE), the Foundation for Women’s Cancer (FWC) and The Harris Poll, the survey aimed to quantify patients’ perspectives on topics including the impact of treatment on daily life, preferences regarding treatment options, the role of shared decision-making, and more.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Endometrial cancer, the most common type of uterine cancer, is the sixth most common cancer in women across the globe, with more than 60,000 new diagnoses in the U.S. each year. In this survey, patients reported that EC and its treatment had negatively impacted not just their physical health, but also social, mental, sexual and financial wellbeing.

Chemotherapy – which is a standard component of the first systemic treatment patients receive ("first-line") – was reported as taking an emotional and physical toll on patients, manifesting in deeply personal ways. While it remains an important step in the clinical paradigm for EC treatment, chemotherapy is not the only option available to patients for whom another course of treatment ("second-line") is necessary. The survey uncovered a strong desire from patients to be more engaged in clinical decision-making, especially to be informed about all available treatment options and their respective side effects.

"These survey results quantify what many of us have been hearing from our patients for years: that they feel the burden of treatment and they want to be informed partners in decisions about their care," said lead author Ginger J. Gardner, MD, FACOG, Gynecologic Oncologist, Memorial Sloan Kettering Cancer Center and Chair, FWC. "These findings are a clear call to action for providers in our field to ensure patients understand their options and have a voice in treatment conversations at every stage of their journey."

Key Findings: Chemotherapy Experiences and Preferences

When looking at all respondents (N=119), the survey found:

70% of patients reported that the burden of chemotherapy treatment was almost as much as the burden of the disease itself, and of those patients who received multiple lines of chemotherapy (n=64)*, 41% reported that their second-line of chemotherapy was worse than the first.
75% of those patients who had received multiple lines of chemotherapy* reported that the treatments had taken a toll on their personal lives.
*Denotes results based on small sample size (n=50-99); should be interpreted as directional only
95% of patients experienced hair loss (alopecia) with their chemotherapy treatment and 82% said that they would prefer a treatment option that causes less hair loss than chemotherapy, if one were available and applicable to them.
Beyond the immediate impact of treatment, patients reported a range of long-term side effects — most commonly fatigue (51%), followed by neuropathy (42%), trouble concentrating or remembering things (35%) and alopecia (35%).
71% of patients reported that they would prefer not to receive chemotherapy again in the future.
Key Findings: Treatment Decision-Making and Patient Education

When looking at all respondents (N=119), the survey found:

Only around 2 in 5 patients (42%) reported that they shared decision-making equally with their doctor and 79% indicated they wish their provider spent more time discussing what matters to them when it comes to their treatment.
9 in 10 patients (91%) wanted to know more about EC treatment options beyond chemotherapy.
92% of patients said they would prefer a treatment plan personalized to them over a one-size-fits-all approach.
Other Findings of Note: Differences in Treatment Experiences and Perceptions*

When looking specifically at respondents who identified as a person of color (n=47), the survey found:

They were less likely to feel informed about their EC treatment options overall (62% vs. 79% of white respondents);
70% reported spending 5 or more hours for a typical chemotherapy visit including scheduling and confirming appointments, getting to and from the appointment, and receiving treatment, while 55% of white respondents reported the same; and
74% agreed that they would prefer not to receive chemotherapy again in the future vs. 69% of white respondents.
*Denotes results based on extremely small sample size (n<50); should be interpreted as directional only

"It’s important that clinicians understand and acknowledge that there is a ‘trust gap,’ where patients of color may understandably doubt that their voices are truly being heard," said study author Adrienne Moore, President, ECANA. "In terms of treatment options, when the harsh physical toll of chemotherapy is compounded by the pressures of family, finances, and outside stressors – which often fall more heavily on communities of color – the combined burden can lead many to seek alternatives over repeating a chemotherapy treatment experience."

"The results of this survey provide a powerful reminder to the medical community that behind every data point is a person navigating one of the most difficult experiences of their life," said study author Sue Friedman, MD, Executive Director, FORCE. "So many of the people I connect with describe feeling overwhelmed by their treatment experience and wishing they had more time, more information, and more of a voice in their care. I encourage all patients to speak up, ask questions, and work with their healthcare team to build a treatment plan that reflects what matters most to them."

Findings from the survey will be presented as a poster, Endometrial Cancer: The Patient Voice is Center Stage, at the SGO Annual Meeting on Women’s Cancer, taking place April 10–13, 2026, in San Juan, Puerto Rico. The poster presentation (Abstract #1356) will happen in Exhibit Hall B on Sunday, April 12, 2026 from 11:00 AM–12:00 PM AST and 4:00–4:45 PM AST.

About the Survey

The Endometrial Cancer Patient Experience Survey was conducted online within the United States between April 21 and July 7, 2025, by The Harris Poll on behalf of Eisai Inc. in collaboration with ECANA, FORCE, and FWC. A total of 571 individuals were recruited to participate through a Harris Poll affiliate and through ECANA’s patient list, of whom 484 underwent eligibility screening (participation rate = 85%). Eligible respondents were ≥18 years of age, assigned female at birth, residents of the United States, diagnosed by a healthcare provider with uterine/endometrial/womb cancer and had received at least one line of prior chemotherapy. Of the 484 who underwent eligibility screening, 119 met the criteria for survey completion and subsequent data analysis (ECANA patient list, n=21; Harris Poll affiliate, n=98).

Select demographic and clinical characteristics of survey respondents included:

Median age: 59 years
Race/ethnicity: 61% White, 22% Hispanic, 16% Black/African American, 1% Asian
Mean time from first experiencing symptoms to EC diagnosis: 3 years
Treatment history (ever received): chemotherapy (100%), surgery (93%), radiation therapy (85%), immunotherapy (50%), oral targeted therapy (42%), hormonal therapy (40%)
54% received multiple prior lines of chemotherapy; 46% received one prior line of chemotherapy
Raw data were not weighted and are therefore only representative of the individuals who completed the survey. For this study, the patient sample data are accurate to within ±8.9 percentage points using a 95% confidence level. This credible interval will be wider among subsets of the surveyed population of interest. All sample surveys and polls, whether or not they use probability sampling, are subject to other multiple sources of error which are most often not possible to quantify or estimate, including, but not limited to coverage error, error associated with nonresponse, error associated with question wording and response options, and post-survey weighting and adjustments.

About Endometrial Cancer

Endometrial cancer begins in the inner lining of the uterus, which is known as the endometrium, and is the most common type of cancer in the uterus. More than 90% of uterine body cancers occur in the endometrium. In the U.S., it is estimated there will be approximately 68,270 patients diagnosed with uterine body cancer and approximately 14,450 patient deaths from the disease in 2026. Globally, endometrial cancer is the sixth most common cancer in women and the 15th most common cancer overall. Despite these figures, endometrial cancer is severely underfunded relative to its rapidly increasing mortality rate. Following primary treatment, patients face a risk of their cancer returning, often as distant metastasis, which is associated with poorer outcomes.

(Press release, Eisai, APR 10, 2026, View Source [SID1234664303])